Syngene International Ltd

Syngene International Earnings Call: Key Takeaways

Syngene faces a transition year in FY27 as the Librela de-stocking headwind masks underlying momentum in biologics and research services.

Syngene International Earnings Call: Key Takeaways

Syngene Q4 FY26 revenue grew 2% YoY to Rs 1,037 Cr with 29% EBITDA margin. Full year FY26 revenue reached Rs 3,739 Cr, driven by integrated CRDMO services.

Syngene International Earnings Call: Key Takeaways

Syngene reported Q4 FY26 revenue of ₹1,037 Cr (up 2% YoY) and FY26 revenue of ₹3,739 Cr (up 3% YoY). Management announced leadership transitions including a new CEO effective July 2026.

Syngene International Dividend

Syngene International's board recommended a final dividend of ₹1.25 per equity share for FY26. The record date is June 26, 2026, with payment expected by August 27, 2026, subject to shareholder approval at the AGM scheduled for July 29, 2026.

Syngene International Board Meeting Outcome

Syngene International Limited's board approved the appointment of Mr. Vijaya Chandru and Mr. Arun Chandavarkar as Independent Directors for three-year terms starting July 2026. Additionally, Ms. Vinita Bali was appointed as a Non-Executive Director for a one-year term. These appointments bring significant expertise in biotechnology, AI, and global business leadership to the board.

Syngene International Management Change

Syngene International Limited has appointed M/s. S. R. Batliboi & Associates LLP as its Statutory Auditor for a five-year term (60 months) effective July 29, 2026. The appointment was approved during a board meeting on April 29, 2026.

Execution

60 months

Syngene International Other Announcement

Syngene International announced an updated list of KMPs authorized to determine event materiality. Effective July 01, 2026, Mr. Siddharth Mittal will succeed Mr. Peter Bains as Managing Director and CEO. Mr. Deepak Jain (CFO) and Mr. Chethan Yogesh (CS) remain authorized alongside the new CEO.

Syngene International Employee Stock Options

Syngene International Limited allotted 7,29,727 equity shares worth ₹0.73 Crore to the Syngene Employee Welfare Trust under its 2023 Long Term Incentive Plan. This issuance increases the company's total paid-up share capital to ₹403.67 Crore. The allotment was made at an exercise price of ₹10 per share.

Value

₹0.73 Cr

Syngene International Management Change

Syngene International approved the appointment of Mr. Vijaya Chandru and Mr. Arun Chandavarkar as Independent Directors for three-year terms starting July 2026. Additionally, Ms. Vinita Bali was reappointed as a Non-Executive Director for one year. These leadership updates, subject to shareholder approval, aim to strengthen the board's strategic oversight and governance.

Execution

3 years for new directors; 1 year for reappointed director

Syngene International Results Update

Syngene International reported full-year FY26 revenue of ₹3,739 Crore, up 3% year-on-year. Q4 revenue grew 2% to ₹1,037 Crore. The company announced leadership changes, with Ms. Kiran Mazumdar-Shaw becoming Executive Chairperson and Mr. Siddharth Mittal appointed as CEO effective July 2026. A final dividend of ₹1.25 per share was recommended.

Value

₹3,739 Cr

Syngene International Q4 FY26 Results: Net Profit ₹147.9 Cr, Down 19.3% YoY

Syngene International Ltd reported revenue from operations of ₹1,036 Cr (+1.8% YoY) and net profit of ₹147.9 Cr (-19.3% YoY) for Q4 FY26.

Key figure

Net profit ₹147.9 Cr · -19.3% YoY

Syngene International Financial Results

Syngene International reported FY26 consolidated total income of ₹3,809.4 Crore with a net profit of ₹316.7 Crore. The Board recommended a final dividend of ₹1.25 per share. It also approved the appointment of M/s S. R. Batliboi & Associates LLP as statutory auditors for five years starting from the 33rd AGM.

Value

₹3,809 Cr

Syngene International Board Meeting Outcome

Syngene International Limited has scheduled a Board Meeting on April 29, 2026, to consider audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also recommend a final dividend. Trading windows remain closed from April 1 until May 1, 2026.

Syngene International Board Meeting Outcome

Syngene International Ltd will hold a Board Meeting on April 29, 2026, to approve audited financial results for the quarter and year ending March 31, 2026. The board will also consider recommending a final dividend. Consequently, the trading window is closed from April 01 to May 01, 2026.

Syngene International Q3 FY26 Results: Net Profit ₹15 Cr, Down 88.5% YoY

Syngene International Ltd reported net profit of ₹15 Cr (-88.5% YoY) for Q3 FY26.

Key figure

Net profit ₹15 Cr · -88.5% YoY